Canada Markets close in 5 hrs 26 mins

Mauna Kea Technologies SA (MKEAF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.40000.0000 (0.00%)
As of 08:44AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close1.4000
Open1.4000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.4000 - 1.4000
52 Week Range1.3300 - 2.2200
Volume1,000
Avg. Volume0
Market Cap58.675M
Beta (5Y Monthly)1.86
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • Business Wire

    Mauna Kea Technologies Provides Business Update

    PARIS & BOSTON, January 13, 2022--Regulatory News: Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces a board-approved plan designed to reduce operating expenses and maximize capital resources in order to support the Company's strategic focus on the use of Cellvizio as an aid for real-time characterization of lung cancer and for molecular imaging g

  • Business Wire

    Mauna Kea Technologies Announces Strategic Realignment

    PARIS & BOSTON, December 13, 2021--Regulatory News: Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announced a realignment of the organization designed to improve operating efficiency, increase the company’s cash runway, and focus resources on Cellvizio’s highest potential clinical applications, including interventional pulmonology and molecular imaging.

  • Business Wire

    Mauna Kea Technologies Announces a New Publication Demonstrating the Economic Benefit of Cellvizio® for Pancreatic Cyst Management

    PARIS & BOSTON, November 17, 2021--Regulatory News: Mauna Kea Technologies (Euronext: MKEA) (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces a new peer-reviewed publication showing the significant healthcare cost savings of using Cellvizio® as an adjunct to the standard of care for the management of pancreatic cystic lesions (PCLs).